Life Sciences Tools and Services
Company Overview of Cirrus Pharmaceuticals, Inc.
Cirrus Pharmaceuticals, Inc. operates as a contract pharmaceutical development company. It develops inhalation and nasal products, including pressurized metered dose inhalers, dry powder inhalers, nebulizer solutions and suspensions, nasal sprays, and novel delivery systems; oral dosage forms, which include liquids, powders, and capsules; parenteral products; and topical and transdermal dosage forms, such as gels, creams, ointments, lotions, pastes, and sprays. The company’s services include analytical services, preformulation, formulation development, device evaluation, stability testing, and manufacturing support. It offers its services to pharmaceutical, biotechnology, veterinary, cosmeti...
511 Davis Drive
Morrisville, NC 27560
Founded in 1997
Key Executives for Cirrus Pharmaceuticals, Inc.
Co-Founder, Chief Executive Officer and President
Director of Accounting and Finance
Director of Business Development
Chairman of Kemwell Biopharma Pvt. Ltd and Managing Director of Kemwell Biopharma Pvt. Ltd
Compensation as of Fiscal Year 2016.
Cirrus Pharmaceuticals, Inc. Key Developments
Cirrus Pharmaceuticals, Inc. Ready to Launch Clinical Trial Manufacturing at Raleigh-Durham Site
Feb 9 16
Cirrus Pharmaceuticals announced that it is ready to launch its services for manufacturing cGMP materials for early phase clinical trials in its newly constructed flexi-suite at its Raleigh-Durham, USA, site. The typical batch size offering is up to 25L and Cirrus will be able to perform one and two-step filling as well as cold filling for suspension and solution MDIs. Other than MDIs in the inhaled dosage forms, the company will offer clients dry powder filling in capsules for Dry Powder Inhalers (DPI), and manufacture of nasal solutions, suspensions, and powders.
Andrew Hamer Joins Cirrus Pharmaceuticals as VP R&D
Aug 14 15
Cirrus Pharmaceuticals announced that Andrew Hamer has joined as VP R&D. Andrew previously worked at GlaxoSmithKline as Senior Director R&D Operations in RTP.
Cirrus Pharmaceuticals to Invest in Flexible cGMP Suite in its Facility in RTP, North Carolina
Oct 30 14
Cirrus Pharmaceuticals announced that it will be investing in a flexible cGMP suite in its facility in RTP, North Carolina. With the addition of the cGMP suite, Cirrus will be able to extend its offerings in the US from contract development to manufacturing.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 18, 2016